Dapagliflozin restores insulin and growth hormone secretion in obese mice.

The well-documented hormonal disturbance in a general obese population is characterised by an increase in insulin secretion and a decrease in growth hormone (GH) secretion. Such hormonal disturbance promotes an increase in fat mass, which deteriorates obesity and accelerates the development of insulin resistance and type 2 diabetes. While the pathological consequence is alarming, the pharmaceutical approach attempting to correct such hormonal disturbance remains limited. By applying an emerging anti-diabetic drug, the sodium-glucose cotransporter 2 inhibitor, dapagliflozin (1mg/kg/day for 10 weeks), to a hyperphagic obese mouse model, we observed a significant improvement in insulin and GH secretion as early as 4 weeks after the initiation of the treatment. Restoration of pathological disturbance of insulin and GH secretion reduced fat accumulation and preserved lean body mass in the obese animal model. Such phenotypic improvement followed with concurrent improvements in glucose and lipid metabolism, insulin sensitivity, as well as the expression of metabolic genes that were regulated by insulin and GH. In conclusion, 10 weeks of treatment with dapagliflozin effectively reduces hyperinsulinemia and restores pulsatile GH secretion in the hyperphagic obese mice with considerable improvement in lipid and glucose metabolism. Promising outcomes from this study may provide insights into drug intervention to correct hormonal disturbance in obesity to delay the diabetes progression.

[1]  F. Pattou,et al.  The GLP1R Agonist Liraglutide Reduces Hyperglucagonemia Induced by the SGLT2 Inhibitor Dapagliflozin via Somatostatin Release. , 2019, Cell reports.

[2]  Nathan R. Qi,et al.  Hypothalamic POMC or MC4R deficiency impairs counterregulatory responses to hypoglycemia in mice , 2018, Molecular metabolism.

[3]  R. Kineman,et al.  Adult-Onset Hepatocyte GH Resistance Promotes NASH in Male Mice, Without Severe Systemic Metabolic Dysfunction. , 2018, Endocrinology.

[4]  H. Kaneto,et al.  Protective effects of the SGLT2 inhibitor luseogliflozin on pancreatic β‐cells in db/db mice: The earlier and longer, the better , 2018, Diabetes, obesity & metabolism.

[5]  H. Arima,et al.  Ipragliflozin, a SGLT2 Inhibitor, Reduced Body Weight and Fat Mass but Not Muscle Mass in Japanese Type 2 Diabetic Patients Treated with Insulin—A Randomized Clinical Trial , 2018, Diabetes.

[6]  E. Wolf,et al.  Animal models of obesity and diabetes mellitus , 2018, Nature Reviews Endocrinology.

[7]  D. Leroith,et al.  Long-term treatment with the ghrelin receptor antagonist [d-Lys3]-GHRP-6 does not improve glucose homeostasis in nonobese diabetic MKR mice. , 2018, American journal of physiology. Regulatory, integrative and comparative physiology.

[8]  D. Leroith,et al.  Hexarelin, a Growth Hormone Secretagogue, Improves Lipid Metabolic Aberrations in Nonobese Insulin‐Resistant Male MKR Mice , 2017, Endocrinology.

[9]  M. Wang,et al.  Effects of canagliflozin on weight loss in high-fat diet-induced obese mice , 2017, PloS one.

[10]  A. Bjourson,et al.  Metabolic and neuroprotective effects of dapagliflozin and liraglutide in diabetic mice. , 2017, The Journal of endocrinology.

[11]  S. Kaneko,et al.  SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice , 2017, EBioMedicine.

[12]  T. Iwasaki,et al.  Chronic hyperinsulinemia contributes to insulin resistance under dietary restriction in association with altered lipid metabolism in Zucker diabetic fatty rats. , 2017, American journal of physiology. Endocrinology and metabolism.

[13]  James D. Johnson,et al.  A causal role for hyperinsulinemia in obesity. , 2017, The Journal of endocrinology.

[14]  T. Okada,et al.  Canagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates obesity‐induced inflammation in the nodose ganglion, hypothalamus, and skeletal muscle of mice , 2017, European journal of pharmacology.

[15]  H. Kaneto,et al.  Beneficial effects of sodium–glucose cotransporter 2 inhibitors for preservation of pancreatic β‐cell function and reduction of insulin resistance , 2016, Journal of diabetes.

[16]  J. Veldhuis,et al.  Hyperphagia in male melanocortin 4 receptor deficient mice promotes growth independently of growth hormone , 2016, The Journal of physiology.

[17]  J. Cutrin,et al.  Empagliflozin Protects against Diet-Induced NLRP-3 Inflammasome Activation and Lipid Accumulation , 2016, The Journal of Pharmacology and Experimental Therapeutics.

[18]  James D. Johnson,et al.  Suppressing hyperinsulinemia prevents obesity but causes rapid onset of diabetes in leptin-deficient Lepob/ob mice , 2016, Molecular metabolism.

[19]  F. Pattou,et al.  Glucose-Dependent Insulinotropic Peptide Stimulates Glucagon-Like Peptide 1 Production by Pancreatic Islets via Interleukin 6, Produced by α Cells. , 2016, Gastroenterology.

[20]  H. Katagiri,et al.  Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, Acutely Reduces Energy Expenditure in BAT via Neural Signals in Mice , 2016, PloS one.

[21]  T. Kadowaki,et al.  Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice. , 2016, Endocrinology.

[22]  D. Cuthbertson,et al.  Energy balance and metabolic changes with sodium‐glucose co‐transporter 2 inhibition , 2016, Diabetes, obesity & metabolism.

[23]  M. Blüher,et al.  The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin. , 2016, Metabolism: clinical and experimental.

[24]  R. DeFronzo,et al.  Effect of Dapagliflozin With and Without Acipimox on Insulin Sensitivity and Insulin Secretion in T2DM Males. , 2016, The Journal of clinical endocrinology and metabolism.

[25]  G. Shulman,et al.  The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. , 2016, The Journal of clinical investigation.

[26]  W. Wilkison,et al.  Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male Mice. , 2015, Journal of clinical and experimental hepatology.

[27]  Dorothy D. Sears,et al.  Intermittent Fasting and Human Metabolic Health. , 2015, Journal of the Academy of Nutrition and Dietetics.

[28]  F. Pattou,et al.  Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion , 2015, Nature Medicine.

[29]  Jessica L. Cohen,et al.  A major role of insulin in promoting obesity-associated adipose tissue inflammation , 2015, Molecular metabolism.

[30]  M. Lewitt,et al.  The Insulin-Like Growth Factor System in Obesity, Insulin Resistance and Type 2 Diabetes Mellitus , 2014, Journal of clinical medicine.

[31]  D. Chia.  Minireview: mechanisms of growth hormone-mediated gene regulation. , 2014, Molecular endocrinology.

[32]  J. D. do Carmo,et al.  The brain melanocortin system, sympathetic control, and obesity hypertension. , 2014, Physiology.

[33]  M. Sasamata,et al.  SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. , 2014, European journal of pharmacology.

[34]  R. DeFronzo,et al.  Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. , 2014, The Journal of clinical investigation.

[35]  T. Heise,et al.  Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. , 2014, The Journal of clinical investigation.

[36]  J. Borén,et al.  Ectopic lipid storage and insulin resistance: a harmful relationship , 2013, Journal of internal medicine.

[37]  G. Johannsson,et al.  The GH/IGF-1 axis in obesity: pathophysiology and therapeutic considerations , 2013, Nature Reviews Endocrinology.

[38]  C. Kahn,et al.  Insulin and IGF-I inhibit GH synthesis and release in vitro and in vivo by separate mechanisms. , 2013, Endocrinology.

[39]  J. Speakman,et al.  The ‘39 steps’: an algorithm for performing statistical analysis of data on energy intake and expenditure , 2013, Disease Models & Mechanisms.

[40]  M. Cerf.  Beta Cell Dysfunction and Insulin Resistance , 2013, Front. Endocrinol..

[41]  James D. Johnson,et al.  Hyperinsulinemia drives diet-induced obesity independently of brain insulin production. , 2012, Cell metabolism.

[42]  M. Pelleymounter,et al.  Weight Loss Induced by Chronic Dapagliflozin Treatment Is Attenuated by Compensatory Hyperphagia in Diet‐Induced Obese (DIO) Rats , 2012, Obesity.

[43]  J. Veldhuis,et al.  The decline in pulsatile GH secretion throughout early adulthood in mice is exacerbated by dietary-induced weight gain. , 2012, Endocrinology.

[44]  M. Waters,et al.  GH does not modulate the early fasting-induced release of free fatty acids in mice. , 2012, Endocrinology.

[45]  Hui-yu Liu,et al.  Insulin and insulin signaling play a critical role in fat induction of insulin resistance in mouse. , 2011, American journal of physiology. Endocrinology and metabolism.

[46]  M. Waters,et al.  Development of a method for the determination of pulsatile growth hormone secretion in mice. , 2011, Endocrinology.

[47]  A. Waisman,et al.  Metabolic Impact of Adult-Onset, Isolated, Growth Hormone Deficiency (AOiGHD) Due to Destruction of Pituitary Somatotropes , 2011, PloS one.

[48]  J. Horowitz,et al.  The pattern of growth hormone delivery to peripheral tissues determines insulin-like growth factor-1 and lipolytic responses in obese subjects. , 2009, The Journal of clinical endocrinology and metabolism.

[49]  J. Kopchick,et al.  Growth hormone improves body composition, fasting blood glucose, glucose tolerance and liver triacylglycerol in a mouse model of diet-induced obesity and type 2 diabetes , 2009, Diabetologia.

[50]  B. Wajchenberg.  beta-cell failure in diabetes and preservation by clinical treatment. , 2007, Endocrine reviews.

[51]  M. Koutsilieris,et al.  The role of the insulin-like growth factor 1 (IGF-1) in skeletal muscle physiology. , 2007, In vivo.

[52]  J. Giacobino,et al.  The control of UCP1 is dissociated from that of PGC‐1α or of mitochondriogenesis as revealed by a study using β‐less mouse brown adipocytes in culture , 2006 .

[53]  R. Kineman,et al.  Impact of obesity on the growth hormone axis: evidence for a direct inhibitory effect of hyperinsulinemia on pituitary function. , 2006, Endocrinology.

[54]  J. Giacobino,et al.  The control of UCP1 is dissociated from that of PGC-1alpha or of mitochondriogenesis as revealed by a study using beta-less mouse brown adipocytes in culture. , 2006, FEBS letters.

[55]  L. Tartaglia,et al.  Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. , 2003, The Journal of clinical investigation.

[56]  Tim Cheetham,et al.  Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. , 2003, The New England journal of medicine.

[57]  J. L. Messina,et al.  Growth Hormone-induced Differential Desensitization of STAT5, ERK, and Akt Phosphorylation* , 2002, The Journal of Biological Chemistry.

[58]  G. A. Miller,et al.  Misunderstanding analysis of covariance. , 2001, Journal of abnormal psychology.

[59]  S. Grottoli,et al.  The GH/IGF-I axis in obesity: influence of neuroendocrine and metabolic factors , 2000, International Journal of Obesity.

[60]  S. O’Rahilly,et al.  A frameshift mutation in MC4R associated with dominantly inherited human obesity , 1998, Nature Genetics.

[61]  Y. Song,et al.  Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone , 1997, International Journal of Obesity.

[62]  R. Cone,et al.  Targeted Disruption of the Melanocortin-4 Receptor Results in Obesity in Mice , 1997, Cell.

[63]  M L Johnson,et al.  Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man. , 1991, The Journal of clinical endocrinology and metabolism.

[64]  M. Shaw,et al.  Basal plasma growth hormone levels in man: new evidence for rhythmicity of growth hormone secretion. , 1990, The Journal of clinical endocrinology and metabolism.

[65]  J. Jansson,et al.  Pulsatile intravenous growth hormone (GH) infusion to hypophysectomized rats increases insulin-like growth factor I messenger ribonucleic acid in skeletal tissues more effectively than continuous GH infusion. , 1988, Endocrinology.

[66]  K. Alberti,et al.  Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man. , 1988, The Journal of clinical investigation.

[67]  J. Martin,et al.  Ultradian growth hormone rhythm in the rat: effects of feeding, hyperglycemia, and insulin-induced hypoglycemia. , 1976, Endocrinology.